Drs. Benjamin Levy and Alex Spira discuss the emerging role of TROP2 as a therapeutic target in non-small cell lung cancer (NSCLC) on ReachMD. They delve into the mechanisms and clinical implications of TROP2-targeted antibody-drug conjugates (ADCs), highlighting ongoing clinical trials evaluating their safety and efficacy. The conversation covers the potential of these therapies to change treatment paradigms, especially in the context of TROP2 overexpression associated with poor prognosis in lung cancers. They also address the nuances of managing side effects and the importance of understanding TROP2's role in cancer regulation, underscoring the significance of keeping up-to-date with the latest clinical trial data in this rapidly evolving field.
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Benjamin Levy, MD
Associate Professor
Johns Hopkins Sidney Kimmel Cancer Center
Washington, DCDr. Levy has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, DSI, JanssenAlexander Spira, MD, PhD, FACP
Medical Oncologist
Director of VCS Research Institute
Director of VCS Phase 1 Program
Medical Director, US Oncology Lung Program
Fairfax, VADr. Spira has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Ownership Interests: Lilly
Consulting Fees: Amgen, Black Diamond Therapeutics, Gritstone Bio, Incyte, Janssen Research & Development, Jazz Pharmaceuticals, Lilly, Mersana, Mirati Therapeutics, Novartis, Regeneron, Sanofi, Takeda
Research: Astellas Pharma, AstraZeneca, Boehringer Ingelheim, LAM Therapeutics, MedImmune, Novartis, Regeneron, RocheReviewers/Content Planners/Authors:
- Jorge Bacigalupo has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- William Mencia, MD has nothing to disclose.
- Tim Person has nothing to disclose.
- Mara Siegel has nothing to disclose.
- Rosanne Straus, PharmD, MBA has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Discuss efficacy and patient response to combination treatment with emerging TROP2-directed ADCs in the first- and second-line treatment of patients with advanced/metastatic NSCLC
- Identify, mitigate, and manage adverse events associated with TROP2-directed therapies by monitoring both treatment response and patient quality of life
Target Audience
This activity is designed to meet the educational needs of medical oncologists, pathologists, oncology nurses, and oncology pharmacists.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until February 28, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .25 contact hours/.025 CEUs of pharmacy contact hours.1
The Universal Activity Number for this program is JA0006235-0000-23-083-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Corey Casper, MD, MPH
Sudipto Mukherjee, MD, PhD, MPH
Jovanna De La Pena
Prem S. Subramanian, MD, PhD
Fatemeh Rajaii, MD, PhD
Fatemeh Rajaii, MD, PhD
Terry J. Smith, MD